日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-in-human experience of radiopharmaceutical therapy with [(177)Lu]Lu-DOTATATE in patients with advanced multiple myeloma

首次在晚期多发性骨髓瘤患者中应用放射性药物[(177)Lu]Lu-DOTATATE进行治疗的人体试验

Delbart, Wendy; Vercruyssen, Marie; Danieli, Rachele; Marin, Clémentine; Wimana, Zéna; Meuleman, Nathalie; Flamen, Patrick; Woff, Erwin; Karfis, Ioannis

Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

分子影像学预测晚期 HER2 阳性乳腺癌患者对 T-DM1 治疗无反应(ZEPHIR 试验的最终结果)

Mileva, Magdalena; de Vries, Elisabeth G E; Guiot, Thomas; Wimana, Zéna; Deleu, Anne-Leen; Schröder, Carolien P; Lefebvre, Yolene; Paesmans, Marianne; Stroobants, Sigrid; Huizing, Manon; Aftimos, Philippe; Tol, Jolien; Van der Graaf, Winette T A; Oyen, Wim J G; Vugts, Danielle J; Menke-van der Houven van Oordt, C Willemien; Brouwers, Adrienne H; Piccart-Gebhart, Martine; Flamen, Patrick; Gebhart, Géraldine

Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study

PRRT治疗过程中剂量学参数的演变及其对临床实践的潜在影响:来自前瞻性II期LUMEN研究的数据

Danieli, Rachele; Mileva, Magdalena; Marin, Gwennaëlle; Kristanto, Paulus; Delbart, Wendy; Vanderlinden, Bruno; Wimana, Zéna; Hendlisz, Alain; Levillain, Hugo; Reynaert, Nick; Flamen, Patrick; Karfis, Ioannis

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

使用丁硫氨酸亚砜亚胺扰乱氧化还原平衡放射增敏生长抑素受体-2 表达临床前模型对肽受体放射性核素治疗与 177Lu-DOTATATE

Wendy Delbart, Gwennaëlle Marin, Basile Stamatopoulos, Roland de Wind, Nicolas Sirtaine, Pieter Demetter, Marie Vercruyssen, Erwin Woff, Ioannis Karfis, Ghanem E Ghanem, Patrick Flamen, Zéna Wimana

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy

了解 177Lu-DOTATATE 诱导的放射生物学机制与外束放射治疗的比较

Wendy Delbart, Jirair Karabet, Gwennaëlle Marin, Sébastien Penninckx, Jonathan Derrien, Ghanem E Ghanem, Patrick Flamen, Zéna Wimana

Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors

FTO m6A RNA 去甲基化酶的下调促进 EMT 介导的上皮肿瘤进展和对 Wnt 抑制剂的敏感性

Jana Jeschke #, Evelyne Collignon #, Clémence Al Wardi #, Mohammad Krayem #, Martin Bizet, Yan Jia, Soizic Garaud, Zéna Wimana, Emilie Calonne, Bouchra Hassabi, Renato Morandini, Rachel Deplus, Pascale Putmans, Gaurav Dube, Nitesh Kumar Singh, Alexander Koch, Kateryna Shostak, Lara Rizzotto, Robert

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

肿瘤药物渗透测量可能是个性化癌症治疗中被忽视的关键环节

Bartelink, Imke H; Jones, Ella F; Shahidi-Latham, Sheerin K; Lee, Pei Rong Evelyn; Zheng, Yanan; Vicini, Paolo; van 't Veer, Laura; Wolf, Denise; Iagaru, Andrei; Kroetz, Deanna L; Prideaux, Brendan; Cilliers, Cornelius; Thurber, Greg M; Wimana, Zena; Gebhart, Geraldine

Accuracy and precision assessment for activity quantification in individualized dosimetry of (177)Lu-DOTATATE therapy

(177)Lu-DOTATATE 治疗个体化剂量测定中活性定量分析的准确性和精密度评估

Marin, Gwennaëlle; Vanderlinden, Bruno; Karfis, Ioannis; Guiot, Thomas; Wimana, Zena; Flamen, Patrick; Vandenberghe, Stefaan